High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival

International Journal of Cancer

Volumn 122, Issue 4, 2008, Pages 857-863

  Roslind, Anne ^a,c   Johansen, Julia S ^a   Christensen, Ib J ^a   Kiss, Katalin ^a   Balslev, Eva ^a   Nielsen, Dorte L ^a   Bentzen, Jens ^a   Price, Paul A ^b   Andersen, Elo ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biomarker; CHI3LI; Head and neck cancer; Prognosis; YKL 40

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN; GLYCOPROTEIN YKL 40; UNCLASSIFIED DRUG; AUTOANTIGEN; CHI3L1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPHIL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; HEAD AND NECK TUMOR; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIGENS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; GLYCOPROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 38349076275     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23152     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949-55.
3. Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001;23:147-59.
4. Chai RL, Grandis JR. Advances in molecular diagnostics and therapeutics in head and neck cancer. Curr Treat Options Oncol 2006;7:3-11.
5. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006;15:194-202.
6. Johansen JS, Christensen IJ, Riisbro R, Greenall M, Han C, Price PA, Smith K, Brunner N, Harris AL. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat 2003;80:15-21.
7. Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 2003;9:4423-34.
8. Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S, Nielsen HJ. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 2002;95:267-74.
9. Dehn H, Hogdall EV, Johansen JS, Jorgensen M, Price PA, Engelholm SA, Hogdall CK. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obsret Gynecol Scand 2003;82:287-93.
10. Hogdall EV, Johansen JS, Kjaer SK, Price PA, Christensen L, Blaakaer J, Bock JE, Glud E, Hogdall CK. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep 2003;10:1535-8.
11. Dupont J, Tanwar MK, Thaler HT, Fleisher M, Kauff N, Hensley ML, Sabbatini P, Anderson S, Aghajanian C, Holland EC, Spriggs DR. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 2004;22:3330-9.
12. Johansen JS, Drivsholm L, Price PA, Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 2004;46:333-40.
13. Geertsen P, Johansen JS, von der Maase H, Jensen BV, Price PA. High pretreatment serum level of YKL-40 is related to short survival in patients with advanced renal cell carcinoma treated with high-dose continuous intravenous infusion of Interleukin-2. ASCO Annual Meeting Proceedings, 2003. Abstract 1603.
14. Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, Iversen P. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 2006;66:503-13.
15. Diefenbach C, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W, Spriggs D, Fleisher M, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol 2007;104:435-42.
16. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002;62:4364-8.
17. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, Deangelis LM, Holland EC. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 2006;12:5698-704.
18. Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, Larsen J, von der MH. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol 2006;24:798-804.
19. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 2006;106:1130-9.
20. Bergmann OJ, Johansen JS, Klausen TW, Mylin AK, Kristensen JS, Kjeldsen E, Johnsen HE. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin Cancer Res 2005;11:8644-52.
21. Mylin AK, Rasmussen T, Johansen JS, Knudsen LM, Norgaard PH, Lenhoff S, Dahl IM, Johnsen HE. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur J Haematol 2006;77:416-24.
22. Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins RB, et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 2005;11:3326-34.
23. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007 2007;25:2288-94.
24. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
25. Aronson NN, Blanchard CJ, Madura JD. Homology modeling of glycosyl hydrolase family 18 enzymes and proteins. J Chem Inf Comput Sci 1997;37:999-1005.
26. Volck B, Price PA, Johansen JS, Sorensen O, Benfield TL, Nielsen HJ, Calafat J, Borregaard N. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998;110:351-60.
27. Renkema GH, Boot RG, Au FL, Donker-Koopman WE, Strijland A, Muijsers AO, Hrebicek M, Aerts JM. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998;251:504-9.
28. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997;43:221-5.
29. Johansen JS, Williamson MK, Rice JS, Price PA. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992;7:501-12.
30. Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PE. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 2005;96:183-90.
31. Morrison BW, Leder P. Neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 1994;9:3417-26.
32. Junker N, Johansen JS, Andersen CB, Kristjansen PE. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 2005;48:223-31.
33. Roslind A, Johansen JS, Junker N, Nielsen DL, Dzaferi H, Price PA, Balslev E. YKL-40 expression in benign and malignant lesions of the breast: a methodological study. Appl Immunohistochem Mol Morphol, in press.
34. Rehli M, Niller HH, Ammon C, Langmann S, Schwarzfischer L, Andreesen R, Krause SW. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 2003;278:44058-67.
35. Houston DR, Recklies AD, Krupa JC, van Aalten DM. Structure and ligand-induced conformational change of the 39-kDa glycoprotein from human articular chondrocytes. J Biol Chem 2003;278:30206-12.
36. Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-9. J Biol Chem 2003;278:37753-60.
37. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindelov B, Jorgensen K A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135-46.
38. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996;35:553-9.
39. Johansen JS, Jensen BV, Roslind A, Price PA. Is YKL-40 a new therapeutic target in cancer? Expert Opin Ther Targets 2007;11:219-34.
40. Harvey S, Weisman M, O'Dell J, Scott T, Krusemeier M, Visor J, Swindlehurst C. Chondrex: new marker of joint disease. Clin Chem 1998;44:509-16.
41. Hogdall EV, Johansen JS, Kjaer SK, Price PA, Blaakjaer J, Hogdall CK. Stability of YKL-40 concentration in blood samples. Scand J Clin Lab Invest 2001;60:247-51.
42. Royston P. Constructing time-specific reference ranges. Stat Med 1991;10:675-90.
43. Baeten D, Boots AM, Steenbakkers PG, Elewaut D, Bos E, Verheijden GF, Berheijden G, Miltenburg AM, Rijnders AW, Veys EM, de Keyser F. Human cartilage gp-39+,CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 2000;43:1233-43.
44. Saleh MN, Goldman SJ, LoBuglio AF, Beall AC, Sabio H, McCord MC, Minasian L, Alpaugh RK, Weiner LM, Munn DH. CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood 1995;85:2910-7.
45. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B- mediated signalling pathways. Biochem J 2002;365:119-26.
46. Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker FG, et al. Prognostic associations of activated mitogen-activated protein kinase and akt pathways in glioblastoma. Clin Cancer Res 2006;12:3935-41.
47. Sidransky D. Cancer of the head and neck. In: DeVita VT, Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins, 2005;653-62.
48. Nojgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003;39:179-86.